Alison Bays, MD (she/her)
@alisonbays.bsky.social
Academic Rheumatologist in my #BlueSkyEra
Work Interests: vasculitis (GCA), quality improvement, medical education
Creator of Rheumify, a web based question bank for rheumatology fellows, @rheumify
Work Interests: vasculitis (GCA), quality improvement, medical education
Creator of Rheumify, a web based question bank for rheumatology fellows, @rheumify
Both presenters used this slide!
October 28, 2025 at 3:38 PM
Both presenters used this slide!
Dr Schmidt’s closing argument: ultrasound is FUN!
October 28, 2025 at 3:21 PM
Dr Schmidt’s closing argument: ultrasound is FUN!
Our paper made it into the Great Debate! 🎉
October 28, 2025 at 3:17 PM
Our paper made it into the Great Debate! 🎉
87% continue steroids despite a negative temporal artery biopsy anyway 😳
October 28, 2025 at 3:12 PM
87% continue steroids despite a negative temporal artery biopsy anyway 😳
This study was funded by Amgen (which makes romosozumab) and UCB, so there’s a huge potential for bias.
October 28, 2025 at 2:23 PM
This study was funded by Amgen (which makes romosozumab) and UCB, so there’s a huge potential for bias.
Plenary III, Abstract 1727: New study in 41k postmenopausal women with osteoporosis reveals treatment gaps: 52% were at very high fracture risk, yet only 6% received anabolic therapies. Over half (51.7%) of these patients got oral bisphosphonates instead.
October 28, 2025 at 2:22 PM
Plenary III, Abstract 1727: New study in 41k postmenopausal women with osteoporosis reveals treatment gaps: 52% were at very high fracture risk, yet only 6% received anabolic therapies. Over half (51.7%) of these patients got oral bisphosphonates instead.
Summary: irAE patients are not the same as RA patients!
October 28, 2025 at 2:15 PM
Summary: irAE patients are not the same as RA patients!
The T cells in these patients showed increased metabolic activity. Elevated levels of inflammatory molecules (IL-6, IL-12, and type I interferon) may be driving the aggressive T cell behavior. #ACR25
October 28, 2025 at 2:14 PM
The T cells in these patients showed increased metabolic activity. Elevated levels of inflammatory molecules (IL-6, IL-12, and type I interferon) may be driving the aggressive T cell behavior. #ACR25
Patients with immunotherapy-related arthritis rarely showed the typical antibodies found in RA (like rheumatoid factor or anti-CCP antibodies). #ACR25
October 28, 2025 at 2:11 PM
Patients with immunotherapy-related arthritis rarely showed the typical antibodies found in RA (like rheumatoid factor or anti-CCP antibodies). #ACR25
Plenary III, Abstract 1726: Mayo research shows arthritis from cancer immunotherapy is NOT the same as rheumatoid arthritis!
Key finding: It’s driven by overactive T cells, not autoantibodies. This means different treatments may be needed. #ACR25
Key finding: It’s driven by overactive T cells, not autoantibodies. This means different treatments may be needed. #ACR25
October 28, 2025 at 2:09 PM
Plenary III, Abstract 1726: Mayo research shows arthritis from cancer immunotherapy is NOT the same as rheumatoid arthritis!
Key finding: It’s driven by overactive T cells, not autoantibodies. This means different treatments may be needed. #ACR25
Key finding: It’s driven by overactive T cells, not autoantibodies. This means different treatments may be needed. #ACR25
Plenary III: How do MAIT cells cause RA inflammation? They activate synoviocytes and secretion of cytokines in contact with activated MAIT cells.
#ACR25
#ACR25
October 28, 2025 at 1:43 PM
Plenary III: How do MAIT cells cause RA inflammation? They activate synoviocytes and secretion of cytokines in contact with activated MAIT cells.
#ACR25
#ACR25
Plenary III: New study reveals MAIT cells play a pathogenic role in rheumatoid arthritis. These immune cells are decreased in blood but enriched in inflamed joints, where they activate inflammatory responses and tissue damage.
October 28, 2025 at 1:37 PM
Plenary III: New study reveals MAIT cells play a pathogenic role in rheumatoid arthritis. These immune cells are decreased in blood but enriched in inflamed joints, where they activate inflammatory responses and tissue damage.
X-chromosome inactivation has cell type specific effects on IFN driven immunity. More studies are needed in non-TLR7 models to investigate how XCI maintenance promotes autoimmune disease in women.
October 28, 2025 at 1:32 PM
X-chromosome inactivation has cell type specific effects on IFN driven immunity. More studies are needed in non-TLR7 models to investigate how XCI maintenance promotes autoimmune disease in women.
Hypothesis that altered XCI maintenance in female lymphocytes promotes autoimmunity
October 28, 2025 at 1:25 PM
Hypothesis that altered XCI maintenance in female lymphocytes promotes autoimmunity
But what if XCI is impaired?
October 28, 2025 at 1:23 PM
But what if XCI is impaired?
XCI is an X-linked mechanism of epigenetic silencing
October 28, 2025 at 1:22 PM
XCI is an X-linked mechanism of epigenetic silencing
CKD Stage 3 and above increases the risk of supratherapeutic hydoxychloroquine dose
October 28, 2025 at 1:12 PM
CKD Stage 3 and above increases the risk of supratherapeutic hydoxychloroquine dose
